Nasdaq stocks posting largest percentage decreases
AP - Tue Dec 02, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
EVOK: 5.45 (+0.02), CTCM: 4.66 (+0.11), RDCM: 10.68 (-0.15), MCEP: 6.16 (+0.66), QDEL: 25.33 (+0.22), POZN: 9.03 (+0.10), AREX: 4.68 (+0.11)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Dec 02, 11:47AM CST
CY: 13.98 (+0.13), QDEL: 25.33 (+0.22), WLT: 1.57 (-0.09), VNCE: 26.77 (-0.69), ISNS: 2.36 (-0.09), VII: 1.34 (-0.05), NTLS: 4.29 (+0.23), MFRM: 56.28 (-3.46), GSAT: 2.69 (-0.01), MOLG: 2.49 (-0.15), EVOK: 5.45 (+0.02), IDRA: 3.59 (+0.13), SCVL: 25.84 (+0.76), VGGL: 3.43 (+0.28), MIXT: 6.36 (+0.17), ENVI: 1.29 (-0.02), REI: 8.32 (+0.14), TRX: 0.60 (-0.11), DGLY: 14.38 (+0.34), CODE: 32.34 (+0.34)
Evoke clears another hurdle on its path to NDA for metoclopramide nasal spray
Seeking Alpha - at Seeking Alpha - Tue Dec 02, 8:05AM CST
EVOK: 5.45 (+0.02)
Evoke Pharma's EVK-001 Showed No QT Prolongation in Thorough ECG (TQT) Study
GlobeNewswire - Tue Dec 02, 7:30AM CST
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced results from an electrocardiogram (ECG) study that assessed the potential of metoclopramide nasal spray (EVK-001) to increase the cardiac QT and corrected QT (QTc) interval across a range of plasma concentrations. The study was conducted to satisfy a safety requirement by the U.S. Food and Drug Administration (FDA) in support of the submission of a New Drug Application (NDA) for EVK-001, an investigational medication for relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. The study met the pre-specified primary endpoint, demonstrating that EVK-001, at therapeutic and supratherapeutic doses, did not prolong the QT/QTc interval in healthy subjects.
EVOK: 5.45 (+0.02)
Evoke Pharma to Present at LD Micro Conference
GlobeNewswire - Tue Nov 25, 7:31AM CST
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, will host an investor presentation on Thursday, December 4, 2014 at 11:30AM PT at the LD Micro Main Event VII Conference. The conference is being held December 2-4, 2014 at the Luxe Sunset Boulevard Hotel in Los Angeles, California.
EVOK: 5.45 (+0.02)
Dr. Kenneth J. Widder Joins Quidel's Board of Directors
Marketwired - Wed Nov 19, 3:39PM CST
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Kenneth J. Widder, M.D. has agreed to join Quidel's Board of Directors, effective immediately. Quidel's Board has been expanded to eight members.
EVOK: 5.45 (+0.02), QDEL: 25.33 (+0.22)
Supernus Pharmaceuticals (SUPN) in Focus: Stock Up 9.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 19, 8:32AM CST
Supernus Pharmaceuticals, Inc. (SUPN) was a big mover last session, as the company saw its shares nearly 10% on the day.
EVOK: 5.45 (+0.02), AKRX: 37.55 (-2.17), SUPN: 8.72 (+0.08)
Evoke Pharma's (EVOK) CEO Dave Gonyer on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 13, 8:04PM CST
EVOK: 5.45 (+0.02)
Evoke Pharma beats by $0.15
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 3:10PM CST
EVOK: 5.45 (+0.02)
Evoke Pharma Reports Third Quarter 2014 Results
GlobeNewswire - Thu Nov 13, 3:09PM CST
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the third quarter ended September 30, 2014.
EVOK: 5.45 (+0.02)
Evoke Pharma Schedules Webcast and Conference Call for Third Quarter 2014 Financial Results
GlobeNewswire - Thu Nov 06, 7:42AM CST
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the Third Quarter of 2014 on Thursday, November 13, 2014, after the close of the market.
EVOK: 5.45 (+0.02)
Evoke Pharma completes enrollment of ECG Study of EVK-001 for diabetic gastroparesis ahead of schedule
M2 - Wed Sep 10, 6:22AM CDT
Pharmaceutical company Evoke Pharma (NasdaqCM:EVOK) disclosed on Tuesday that it has completed the enrollment in its thorough ECG (electrocardiogram) (QT) study of its lead product candidate EVK-001.
EVOK: 5.45 (+0.02)
Evoke Pharma Announces the Completion of Enrollment in Its Thorough ECG Study for EVK-001
GlobeNewswire - Tue Sep 09, 7:30AM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has completed enrollment in its thorough ECG (QT) study of EVK-001, the Company's lead product candidate. EVK-001 is currently in a Phase 3 clinical trial for the relief of symptoms associated with acute and recurrent gastroparesis in women with diabetes mellitus.
EVOK: 5.45 (+0.02)
Evoke Pharma to Present at the Aegis Capital Corp. 2014 Healthcare & Technology Conference
GlobeNewswire - Thu Sep 04, 7:35AM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that Dave Gonyer, CEO, will present a corporate overview at the Aegis Capital Corp. 2014 Healthcare & Technology Conference, being held September 10-13, 2014 at The Encore at The Wynn in Las Vegas, Nevada. The Company is scheduled to present on Thursday, September 11, 2014 at 2:00pm PT. A copy of the corporate overview will be posted to the company's website following the presentation.
EVOK: 5.45 (+0.02)